Abstract
This report describes the case of a 29-year-old patient with chronic myeloid leukemia in the blast phase who underwent hematopoietic stem cell transplantation (HSCT) after living-donor liver transplantation. Donor selection, conditioning regimens, and graft-versus-host disease (GVHD) prophylaxis are discussed. The patient received a non-myeloablative conditioning regimen and ABO blood group-matched unrelated human leukocyte antigen fully-matched donors. Immunosuppressants tacrolimus and mycophenolate mofetil were administered to prevent GVHD. Maintenance therapy with ponatinib effectively maintained remission. This case highlights the complexities of managing HSCT after solid organ transplantation and suggests strategies for future cases.